{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:20:17Z","timestamp":1790684417964,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi and Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.cmi.2021.07.018","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T19:19:58Z","timestamp":1626895198000},"page":"447.e1-447.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["In\u00a0vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection"],"prefix":"10.1016","volume":"28","author":[{"given":"Francisco Javier","family":"Candel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Santerre Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Longshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2021.07.018_bib1","series-title":"WHO publishes list of bacteria for which new antibiotics are urgently needed","year":"2017"},{"key":"10.1016\/j.cmi.2021.07.018_bib2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ijantimicag.2017.12.012","article-title":"High excess costs of infections caused by carbapenem-resistant Gram-negative bacilli in an endemic region","volume":"51","author":"Vargas-Alzate","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2021.07.018_bib3","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare safety Network at the Centers for Disease Control and Prevention, 2011\u20132014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.cmi.2021.07.018_bib4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fmicb.2019.00080","article-title":"Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options","volume":"10","author":"Sheu","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2021.07.018_bib5","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.07.018_bib6","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/cid\/ciz826","article-title":"Cefiderocol: discovery, chemistry, and in\u00a0vivo profiles of a novel siderophore cephalosporin","volume":"69","author":"Sato","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.07.018_bib7","series-title":"Fetcroja\u00ae (cefiderocol) summary of product characteristics (29 April 2020)","author":"Shionogi","year":"2020"},{"key":"10.1016\/j.cmi.2021.07.018_bib8","series-title":"Fetroja\u00ae (cefiderocol) prescribing information (November 2019)","author":"Shionogi","year":"2019"},{"key":"10.1016\/j.cmi.2021.07.018_bib9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In\u00a0vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015\u20132016: SIDERO-WT-2015","volume":"53","author":"Karlowsky","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2021.07.018_bib10","doi-asserted-by":"crossref","first-page":"e00093","DOI":"10.1128\/AAC.00093-17","article-title":"In\u00a0vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study)","volume":"61","author":"Hackel","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.07.018_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2021.07.018_bib12","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jgar.2020.07.009","article-title":"Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)","volume":"22","author":"Kohira","year":"2020","journal-title":"J\u00a0Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2021.07.018_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12291-012-0250-7","article-title":"Non transferrin bound iron: nature, manifestations and analytical approaches for estimation","volume":"27","author":"Patel","year":"2012","journal-title":"Indian J Clin Biochem"},{"key":"10.1016\/j.cmi.2021.07.018_bib14","author":"International Organization for Standardization","year":"2019"},{"key":"10.1016\/j.cmi.2021.07.018_bib15","series-title":"Antimicrobial susceptibility testing meeting minutes and presentations, January 2016","year":"2016"},{"key":"10.1016\/j.cmi.2021.07.018_bib16","first-page":"144","article-title":"Nonfermenting Gram-negative bacilli other than Pseudomonas aeruginosa and Acinetobacter spp. causing respiratory tract infections in a tertiary care center","volume":"5","author":"Chawla","year":"2013","journal-title":"J\u00a0Glob Infect Dis"},{"key":"10.1016\/j.cmi.2021.07.018_bib17","series-title":"Epidemiology and mechanisms of resistance of extensively drug resistant Gram-negative bacteria","author":"Eichenberger","year":"2019"},{"key":"10.1016\/j.cmi.2021.07.018_bib18","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.3389\/fmicb.2018.02871","article-title":"Heterogeneous colistin-resistance phenotypes coexisting in Stenotrophomonas maltophilia isolates influence colistin susceptibility testing","volume":"9","author":"Martinez-Servat","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2021.07.018_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.07.018_bib20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3389\/fmicb.2015.00893","article-title":"Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options","volume":"6","author":"Chang","year":"2015","journal-title":"Front Microbiol"},{"key":"10.1016\/j.cmi.2021.07.018_bib21","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1093\/cid\/ciz830","article-title":"Treatment options for carbapenem-resistant Gram-negative bacterial infections","volume":"69","author":"Doi","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.07.018_bib22","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/mdr.2018.0027","article-title":"Relationship between biofilm formation and antimicrobial resistance in Gram-negative bacteria","volume":"25","author":"Cepas","year":"2019","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.cmi.2021.07.018_bib23","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1038\/s41598-019-38943-7","article-title":"Resistance mechanisms and population structure of highly drug resistant Klebsiella in Pakistan during the introduction of the carbapenemase NDM-1","volume":"9","author":"Heinz","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2021.07.018_bib24","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1093\/cid\/ciz828","article-title":"Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin","volume":"69","author":"Katsube","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2021.07.018_bib25","doi-asserted-by":"crossref","first-page":"e01437","DOI":"10.1128\/AAC.01437-20","article-title":"Population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infection","volume":"65","author":"Kawaguchi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.07.018_bib26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2021.07.018_bib27","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2021.07.018_bib28","doi-asserted-by":"crossref","first-page":"e01391","DOI":"10.1128\/AAC.01391-17","article-title":"Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis","volume":"62","author":"Kawaguchi","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2021.07.018_bib29","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/aas.12897","article-title":"Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study","volume":"61","author":"Bakke","year":"2017","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.cmi.2021.07.018_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/jac\/28.3.377","article-title":"Uptake of a catecholic cephalosporin by the iron transport system of Escherichia coli","volume":"28","author":"Critchley","year":"1991","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2021.07.018_bib31","series-title":"A multi-site study comparing a commercially prepared dried MIC susceptibility system to the CLSI\/ISO broth microdiluion method for cefiderocol using Gram-negative non-fastidious organisms, abstr AAR-761","author":"Lewis","year":"2019"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21004109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X21004109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:32:49Z","timestamp":1761118369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X21004109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1198743X21004109"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2021.07.018","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2021.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}